New drug cocktail shows promise for tough lung cancer after chemo fails

NCT ID NCT05001971

Completed Disease control Sponsor: Hunan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, anlotinib and penpulimab, in 65 patients with small cell lung cancer whose disease had worsened after initial platinum-based chemotherapy. Anlotinib blocks blood vessel growth to tumors, while penpulimab helps the immune system attack cancer cells. The goal was to see if this combo could shrink tumors or slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anlotinib and Penpulimab
What this could lead to: If successful, this combination could offer a new second-line treatment option for patients with small cell lung cancer whose disease has progressed after initial chemotherapy.
What could go wrong: This is a small, single-arm phase 2 pilot study with no placebo or comparison group, so results may not be definitive. Side effects from the drug combination are possible, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Locations

Nong Yang

Changsha, Hunan, 410000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.